|
OB/GYN Annual Author
Index 2001
[ Subject
| Author ]
[ A | B
| C | D | E |
F | G | H | I
| J | K | L |
M | N | O | P
| Q | R | S | T
| U | V | W |
X | Y | Z ]
A
Abelson AG
Preservation of bone density in postmenopausal women. Dec(suppl):20–24
Women at risk. Jul(suppl):4–9
Ansbacher R
Herbal medicine: focus on phytoestrogens. Jan:36–40
Arias R
A call for clarity in breast care. Oct:11–12
back to top
B
Bachmann G
Vaginal atrophy. Nov(suppl):19–22
Vulvovaginal candidiasis: effects on women's health care. March(suppl):6–7
Bansore S, see Gimovsky
ML
Baum EB
Outpatient physical therapy. Jun(suppl):26–31
Brotzman GL, see Butler
DJ
Brown CS
Psychotropic medications, part 1: use during pregnancy. Jul:21–33
Brown HP
Clinician–patient communication. Nov(suppl):8–10
Emergency contraceptive pills. Mar:15–27
Burke JJ II, see Gallup
DG
Burkman RT
The hormone continuum: accrual of women's health benefits. Jan(suppl):10–24
The hormone continuum: accrual of women's health benefits overview.
Jan(suppl):2–3
Reflections. Aug:8
Transitional management: the use of oral contraceptives in perimenopause.
Jan(suppl):4–9
Butler DJ
Bioterrorism and anthrax anxiety. Dec:8–10
back to top
C
Calhoun AH, see Mannix
LK
Carson SA, see Heard
MJ
Cefalu C
Confusional states in older women. Jun(suppl):16–25
Chesnut CH III
Pharmacotherapeutic options. Jul(suppl):10–14
Choi MW
Menopause and mood. Aug:62–63
Cohen HD
Obesity and metabolic changes in aging women. Jun(suppl):39–43
Collins JA, see Burkman
RT
back to top
D
Davidson MH
Cardiovascular implications of hormonal therapy. Dec(suppl):13–19
Davtyan CA
Mifepristone. Dec:45–50
Dayspring TD
Coronary artery disease prevention in women. Mar:59–65
DeMasi MA
Recurrent nonpuerperal ovarian vein thrombosis. Nov:42–44
Dickerson VM
Access to emergency contraception in the United States. Sep:10–13
Contraception in the perimenopause. Jul:34–42
The OB/GYN as primary care physician. Mar:9–10
back to top
E
Eskew PN
Deciphering the codes. Jan:31
Eskin BA
Common benign conditions of the breast. Oct:44–49
back to top
F
Faro S
Treating vulvovaginal candidiasis. March(suppl):26–31
Vulvovaginal candidiasis: a historical -perspective. March(suppl):4–5
Fiore T
Exercise during pregnancy. Jun:12–18
Foreyt JP, see Volding
DC
Freedman M
Enhancing normal sexual function. Nov(suppl):15–18
Freeman R
Hot flashes: prescription alternatives to ERT/HRT. Apr:63–64
G–I
back to top
G
Gallup DG
Suspicious adnexal masses. May:20–25
Gelfand MM
Estrogen–androgen therapy. Sep:54–55
Gilliam ML
ERT/HRT use in African-American women, part 1: implications for
osteoporosis. Jul:63–67
Gimovsky ML
Breech presentation. Feb:41–46
Gleason BM, see DeMasi
MA
Goldberg J
Private or public: umbilical cord blood should be preserved and
stored. Mar:28–44
Goldstein PJ, see Koklanaris
N
Gorodeski GI
ERT/HRT in diabetic women. Jan:28–30
Graham V, see Koklanaris
N
Greiger-Zanlungo P
HIV and women. Feb:12–18
back to top
H
Heard MJ
Hysterosalpingography. Apr:29–40
Henzl MR, see Faro
S
Hill M, see Brown CS
Hudson T
Managing perimenopausal symptoms: an integrative medicine approach.
Aug:33–40
Natural progesterone. Apr:43–48
Soy and women's health. Dec:26–37
back to top
I
Irrgang JJ, see Baum
EB
back to top
J
Johnson KC
Hormone replacement and cardiovascular disease. Oct(suppl):5–9
back to top
K
Kakuni AM, see Volding
DC
Kaplan GA, see Petrikovsky
BM
Kaunitz AM, see also Burkman
RT
Reduced-dose oral contraceptives. Sep:24–36
Keith LG, see also Oleszczuk
JJ
Breast cancer. Oct:16–29
Kingsberg S
Menopause and sexual functioning. Jun:35–36
Knutson C, see Brown
HP
Koklanaris N
Antenatal corticosteroids. Dec:12–21
Kowey PR
The role of potassium. Oct(suppl):10–13
Krivak TC
Tubo-ovarian abscess. Jun:43–49
Kronenberg F
Hot flashes: nonprescription alternatives to ERT/HRT. Mar:50–52
Krychman M
Sexual dysfunction: current issues. Nov(suppl):4–7
back to top
L
Laguens M, see Keith
LG
Levinson RS
Vulvovaginal candidiasis: bioadhesive -technology. March(suppl):21–23
Lobo RA
Progestogens: new approaches. Oct(suppl):19–22
Recent findings in cardiovascular disease. Oct(suppl):3–4
Lyon DS
Borderline personality disorder. Nov:32–41
back to top
M
Maidman J
Seizure prophylaxis: magnesium sulfate advised in pre-eclamptic
parturients. Nov:22–31
Mannix LK
Menstrual migraine. Sep:46–51
Mariani EP, see Faro
S
Markenson GR
Diagnosing the cause of fetal demise. Aug:43–50
Martens M
Vulvovaginal candidiasis: a consensus -summary. March(suppl):24–25
Mayeaux EJ Jr
Work-up of bacterial vaginosis. May:29–35
McFee RB
Chest pain in female adolescents. Aug:20–30
McNamara DE
Medical concerns of endurance athletes. Jul:44–54
Mirhashemi R
Hereditary gynecologic malignancies. Jun:23–34
Mitchell ES, see Woods
NF
Monif G
Vulvovaginal candidiasis: diagnostic issues. March(suppl):10–11
back to top
N
Nachtigall LE
Colorectal cancer: does estrogen play a protective role? Nov:45–46
Nieves-Neira W, see Mirhashemi
R
Nolan TE
Civility–it's to our advantage. Apr:7–8
Coding and compliance can't be ignored. Jan:9–10
New members add dimension to board. Jun:9
Novielli KD
Meeting caregivers' health care needs. Jun(suppl):32–38
Meeting the needs of the aging female patient. Jun(suppl):9
back to top
O
Oleszczuk AK, see Keith
LG
Oleszczuk JJ, see also Keith
LG
Triplet pregnancy. Apr:54–59
back to top
P
Parks SM, see Novielli
KD
Petrikovsky BM
Nuchal cord detected on ultrasound. Aug:13–14
Phillips OP
Infertility, part 1: genetic causes in females. Aug:55–59
Infertility, part 2: genetic causes in males. Sep:38–45
Pinkerton JAV
Postmenopausal osteoporosis: pharmacologic options for prevention.
Jul:70–71
Pitt B
Aldosterone-receptor blocking agents. Oct(suppl):14–18
Pope CS
Urinary incontinence: evaluation and nonsurgical management. Jan:41–47
Portman DJ
Hormone replacement therapy. Dec(suppl):25–29
Propst A, see Krivak
TC
Putterman C
Risk factors for osteoporosis. Jul(suppl):2–3
back to top
R
Rabin J, see Pope CS
Reever MM, see Lyon
DS
Richwald GA
External genital warts. Nov:50–56
Robinson J
A contrary view: routine magnesium sulfate prophylaxis is unnecessary.
Nov:23–31
Rothert M
Counseling for continuance: improving use of ERT/HRT. Dec:43–44
back to top
S
Sammons D, see Wachtel
SS
Sand PK
Overactive bladder in women. Jun(suppl):10–15
Sepilian V, see Eskin
BA
Shulman LP, see also Faro
S, Krychman M, Wachtel SS
Evidence-based medicine, revisited. Nov:10
New medicine, same old problems. Feb:9
Sexuality: the evaluation and care of women. Nov(suppl):3
Vulvovaginal candidiasis: safety and drug -interactions. March(suppl):19–20
Sidani M
Thyroid disorders in the elderly. Apr:15–25
Simon JA
Surgically induced menopause. Feb:50–51
Skaer TL, see Richwald
GA
Skerrett D
Public UCB banks. Mar:29–44
Sobel J
Candida pathogens and antifungal susceptibility. March(suppl):12–14
Speroff L
Hormone replacement and breast cancer. Dec(suppl):6–12
Starz TW, see Baum
EB
Strachan DD
Evaluation of hair loss. May:39–44
back to top
T
Taylor MB, see Burkman
RT
Trope L
The business of medicine. Jul:11
back to top
U
Unger J
Diabetes management in the new millennium. May:10–12
Pre-conception management of women with type I diabetes. May:45–51
back to top
V
Volding DC
Reducing CVD risk through lifestyle modification. Jun(suppl):44–48
back to top
W
Wachtel SS
Prenatal screening and diagnosis. Jan:21–27
Woods NF
Menopause transition. Oct:37–38
Woodward S
Sleep and menopause. May:57–58
Wysocki DK
Inherited bleeding disorders. Feb:20–27
Wysocki SJ, see Burkman
RT
back to top
Y
Yeo SA, see Fiore T
back to top
Z
Zamorski MA
Anxiety disorders. Feb:31–36
Zieman M
Transdermal contraception. Dec:22–25
back to top
|
